focus -WSS

focus

author：focus 2025-09-27 12:53:49 - browse：14

Photo illustration of Covid 19 testing swabs on a blue background. — Timothy Stenzel led the FDA's diagnostics division during the Covid-19 pandemic, as the agency scrambled to push through and validate accurate Covid tests. Adobe

Timothy Stenzel, the federal regulator who led the Food and Drug Administration’s diagnostics division during the chaotic time of Covid-19 pandemic, has left the agency. The FDA confirmed Thursday that Stenzel, who led the FDA’s office of in vitro diagnostics, retired at the end of 2023.

During the early days of the pandemic, Stenzel was in the middle of a turf battle between the Centers for Disease Control and Prevention and the FDA over the regulation of Covid tests. At one point, the CDC made Stenzel wait at its facility overnight after he arrived for a meeting on Covid test development, Politico reported at the time.

It was a hectic time. Testmakers rapidly introduced new Covid-19 screening products with little data, as it was a brand new virus. The pandemic especially laid bare FDA’s inability to control lab-developed tests (LDTs). Many of the Covid-19 PCR tests fell in this category. Early on, using powers granted by the public health emergency, the FDA required labs to apply for emergency use authorization. But a STAT investigation found that the Department of Health and Human Services told the FDA to stop this measure, despite knowing that many of the tests may have been inaccurate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Patients, doctors press FTC to beef up hospital merger scrutiny

knowledge

WSS

Eli Lilly CEO gives to Mike Pence presidential super PAC

Why the drug industry's warnings on the IRA's impact fall short

Chamber of Commerce, DOJ clash in court over drug prices

'A game

Sea level rise could wash away turtle breeding grounds around the world, researchers say

PBMs drew scrutiny in House hearing — and so did pharma

explore

focus

focus

Trump demands the U.S. pay no more for drugs than other countries … again

PBMs drew scrutiny in House hearing — and so did pharma

Apple is now the first public company to be valued at $3 trillion

Millions may soon lose Medicaid when they don't have to

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Neurocrine congenital adrenal hyperplasia trial succeeds

Sports medicine is finally prioritizing gender equality

How the messy conversation about Dolly changed bioethics

At least 13 dead in Texas as scorching temps continue

Midwives could help bridge maternal health disparities in the U.S.

hotspot

Can medical device makers keep up in the race to treat obesity?

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

Living organ donors deserve priority status for transplants

Grad students accuse University of California of wage theft

Novo: Oral version of Ozempic leads to 15% weight loss

Millions may soon lose Medicaid when they don't have to

hotspot

Wikipedia

knowledge

leisure time